細胞特異性阻害剤と規制ドメインデルタとの相互作用によるc-Jun活性制御:v-とc-Junの違い
1Howard Hughes Medical Institute, University of California, Berkeley 94720.
Cell
|November 16, 1990
まとめ
細胞阻害剤は,A1ドメイン経由でc-Jun転写活性を否定的に調節し,デルタドメインはこの抑制を媒介する. これは,デルタが欠けているv-Junが,c-Junよりも強いアクティベーターである理由を説明します.
科学分野:
- 分子生物学は分子生物学である.
- 遺伝子規制 遺伝子規制
- セルラー・シグナリング
背景:
- c-Junは,細胞の様々なプロセスに関与する転写因子です.
- c-Junの転写活動は,規制ドメインによって調節することができます.
- c-Jun とそのウイルスの同位体,v-Jun. の間の転写特性には違いがあります.
研究 の 目的:
- c-Jun.の転写活性化特性を調査する.
- c-Jun in vivoの活動を制御する規制メカニズムを特定する.
- c-Jun 調節におけるデルタドメインの役割を明らかにする.
主な方法:
- 異なる細胞系におけるc-Junキメラの分析.
- 化学的ジュンタンパク質と細胞抽出物を用いたインビトロ転写アッセイ.
- 調節ドメインと細胞阻害剤の相互作用を調査する.
主要な成果:
- c-Junは,細胞型特異的阻害剤によって否定的に調節される活性化ドメイン (A1) を有する.
- c-Junのデルタドメインは,阻害剤とA1.1との相互作用を促進します.
- v-Junはデルタドメインが欠けていて,抑制が減少したため,より強い転写活性化を示しています.
- A1ドメインとデルタドメインの両方,細胞型特異的な抑圧の対象となります.
結論:
- 特定の細胞因子がc-Junの活性を否定的に調節する.
- デルタドメインは,c-Jun.の細胞タイプ固有の抑制を媒介する上で重要な役割を果たします.
- この発見は,c-Junとv-Junの異なった転写行動に対する分子的な説明を提供する.
さらに関連する動画
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
関連する概念動画
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Regulated Protein Degradation
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Regulated Protein Degradation
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
